Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 1/2003

01.01.2003 | Review Article

The Second Generation of COX-2 Inhibitors

What Advantages Do the Newest Offer?

verfasst von: Dr Dirk O. Stichtenoth, Jürgen C. Frölich

Erschienen in: Drugs | Ausgabe 1/2003

Einloggen, um Zugang zu erhalten

Abstract

The discovery of two cyclooxygenase (COX)-isoenzymes, a constitutive OX-1, serving homeostatic prostanoid synthesis, and an inducible COX-2, responsible for proinflammatory prostanoid production, led to the development of new non-steroidal anti-inflammatory drugs (NSAIDs), the selective COX-2 inhibitors, promising minimal NSAID-typical toxicity with full anti-inflammatory efficacy.
So far, the strategy of selective COX-2 inhibition has been successful. Selective COX-2 inhibitors have significantly less gastrotoxicity and no effects on platelet aggregation. However, with regard to renal adverse events, selective COX-2 inhibitors do not offer a clinically relevant advantage over non-selective inhibitors. Moreover, concerns over the cardiovascular risk of selective COX-2 inhibitors have recently been raised.
The second generation of COX-2 inhibitors with higher COX-2 selectivity was developed with the promise of further reduction of NSAID-typical adverse effects. The leading compounds are valdecoxib, parecoxib, etoricoxib and lumaricoxib. At the present time they have proven efficacy for the treatment of pain and inflammation. Parecoxib as a parenteral, highly selective COX-2 inhibitor has the potential to become the NSAID of choice for treatment of postoperative pain.
In clinical trials, valdecoxib, parecoxib, etoricoxib and lumaricoxib have caused no more endoscopic ulcers than placebo. However, to date, no data on the clinically relevant endpoints perforation, symptomatic ulcer and bleeding are available. Furthermore, no definite conclusions on renal and cardiovascular safety are possible. Current evidence points to a marginal, if any, gain of safety compared with the first generation of COX-2 inhibitors. However, trials with the new COX-2 inhibitors offer the chance to address these open questions of highly selective COX-2 inhibition; that is, thrombogenic risk, sodium and water retention, and interference with tissue repair, in particular, healing of mucosal damage.
Literatur
1.
Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 1971; 231: 232–5
2.
Masferrer JL, Zweifel BS, Seibert K, et al. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 1990; 86: 1375–9PubMedCrossRef
3.
Xie W, Chipman JG, Robertson DL, et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991; 88: 2692–6PubMedCrossRef
4.
Kujubu DA, Fletcher BS, Varnum BC, et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homolohue. J Biol Chem 1991; 266: 12866–72PubMed
5.
Frölich JC. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isozymes. Trends Pharmacol Sci 1997; 18: 30–4PubMedCrossRef
6.
International COX-2 Study Group. The Classification of cyclooxygenase inhibitors. J Rheumatol 1998; 25: 2298–303
7.
8.
9.
Katori M, Majima M. Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors. Inflamm Res 2000; 49: 367–92PubMedCrossRef
10.
Crofford LJ, Lipsky PE, Brooks P, et al. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 2000; 43: 4–13PubMedCrossRef
11.
Stichtenoth DO, Frölich JC. Therapy with preferential and specific COX-2 inhibitors. Internist 2001; 42: 421–6PubMedCrossRef
12.
Fitzgerald GA, Patrono C. The Coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345: 433–42PubMedCrossRef
13.
Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520–8PubMedCrossRef
14.
15.
Talley JJ, Brown DL, Carter JS, et al. 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem 2000; 43: 775–7PubMedCrossRef
16.
Riendeau D, Percival MD, Brideau C, et al. Etoricoxib (MK-0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001; 296: 558–66PubMed
17.
Talley JJ, Bertenshaw SR, Brown DL, et al. N-[[(5-Methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: a potent and selective inhibitor of COX-2 for parenteral administration. J Med Chem 2000; 43: 1661–3PubMedCrossRef
18.
Penning TD, Talley JJ, Bertenshaw SR, et al. Synthesis and biological evaluation of the 1,5 diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-l-yl] benzenesulfonamide (SC-58635, celecoxib). J Med Chem 1997; 40: 1347–65PubMedCrossRef
19.
20.
G.D. Searle LLC. Product Information: Bextra™, valdecoxib. G.D. Searle LLC, Chicago (IL), 2001
21.
Agrawal NGB, Porras AG, Matthews CZ, et al. Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers. J Clin Pharmacol 2001; 41: 1106–10PubMedCrossRef
22.
Curtis SP, Fisher C, Kafka S, et al. Treatment with etoricoxib, a COX-2 selective inhibitor, resulted in clinical improvement in knee osteoarthritis (OA) over 52 weeks. Ann Rheum Dis 2001; 60 Suppl. 1: SAT0064
23.
Curtis SP, Maldonado-Cocco J, Losada BR, et al. Treatment with etoricoxib (MK-0663), a COX-2 selective inhibitor, resulted in maintenance of clinical improvement in rheumatoid arthritis. Ann Rheum Dis 2001; 60 Suppl. 1: FRI0030
24.
Malmstrom K, Kotey P, Coughlin H, et al. Efficacy of etoricoxib, naproxen sodium, and acetaminophen/codeine in acute dental pain. Am Soc Clin Pharmacol Ther 2001; 69: 2
25.
Davies NM, McLachlan AJ, Day RO, et al. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2000; 38: 225–42PubMedCrossRef
26.
G.D. Searle LLC. Product Information: Celebrex®, celecoxib. Chicago (IL): G.D. Searle LLC, 2001
27.
28.
Indocin®, indomethacin. Product Information. West Point (PA): Merck & Co., Inc., 1999
29.
Leese PT, Recker D, Kuss ME. A double-blind, placebo-controlled study to evaluate the effects of valdecoxib, a novel COX-2 specific inhibitor, on platelet function in the elderly. Anesthesiology 2000; 93: 227
30.
Leese PT, Recker D, Kuss ME. The novel COX-2 specific inhibitor valdecoxib, does not affect platelet function in healthy adults. Anesthesiology 2000; 93: 228
31.
Funk CD, Funk LB, Kennedy MB, et al. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J 1991; 5: 2304–12PubMed
32.
Camu F, Beecher T, Recker DP, et al. Valdecoxib, a COX-2-specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty. Am J Ther 2002; 9: 43–51PubMedCrossRef
33.
Ibrahim A, Park S, Feldman J, et al. Effects of parecoxib, a parenteral COX-2-specific inhibitor, on the pharmacokinetics and pharmacodynamics of propofol. Anesthesiology 2002; 96: 88–95PubMedCrossRef
34.
Ibrahim A, Karim A, Feldman J, et al. The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam. Anesth Analg. 2002; 95: 667–73PubMed
35.
Fricke J, Varkalis J, Zwillich S, et al. Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery. Am J Ther 2002; 9: 89–97PubMedCrossRef
36.
Desjardins PJ, Shu VS, Recker DP, et al. A single preoperative oral dose of valdecoxib, a new cyclooxygenase-2 specific inhibitor, relieves post-oral surgery or bunionectomy pain. Anesthesiology 2002; 97: 565–73PubMedCrossRef
37.
Daniels SE, Desjardins PJ, Talwalker S, et al. The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery. J Am Dent Assoc 2002; 133: 611–21
38.
Torri S, Kuss ME, Talwalker SC, et al. The cyclooxygenase (COX)-2 specific inhibitor valdecoxib effectively treats primary dysmenorrhea. Fertil Steril 2001; 76: S95CrossRef
39.
Daniels SE, Talwalker S, Torri S, et al. Valdecoxib, a cyclo-oxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea. Obstet Gynecol 2002; 100: 350–8PubMedCrossRef
40.
Kivitz A, Eisen G, Zhao WW, et al.. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract 2002; 51: 530–7PubMed
41.
Makarowski W, Zhao WW, Bevirt T, et al. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage 2002; 10: 290–6PubMedCrossRef
42.
Bensen W, Weaver A, Espinoza L, et al. Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen. Rheumatology 2002; 41: 1008–16PubMedCrossRef
43.
Sikes DH, Agrawal NM, Zhao WW, et al. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroenterol Hepatol 2002; 14: 1101–11PubMedCrossRef
44.
Agrawal N, Paperiello B, Zhao WW, et al. Supratherapeutic doses of valdecoxib have a reduced incidence of gastroduodenal ulcers compared with conventional therapeutic doses of naproxen in osteoarthritis and rheumatoid arthritis patients [abstract]. Arthritis Rheum 2001; 44: 1917CrossRef
45.
46.
Stichtenoth DO, Frölich JC. Correspondence. N Engl J Med 1998; 338: 685–6PubMed
47.
Noveck RJ, Laurent A, Kuss M, et al. Parecoxib sodium does not impair platelet function in healthy elderly and non-elderly individuals. Clin Drug Invest 2001; 21: 465–76CrossRef
48.
Hubbard R, Kuss M, Talwalker S, et al. Evaluation of parecoxib, a new injectible cyclooxygenase-2-specific inhibitor, for the treatment of pain. Ann Emerg Med 2000; 36: S69
49.
Daniels SE, Kuss M, Mehlisch DR, et al. Pharmacokinetic and efficacy evaluation of intravenous parecoxib in a postsurgical dental pain model. Clin Pharmacol Ther 2000; 67: 91
50.
Mehlisch DR, Kuss M, Bauman A, et al. Correlation of pharmacokinetics (PK) with onset and duration of analgesia of i.m. doses of parecoxib in postoperative dental pain. Clin Pharmacol Ther 2000; 67: PIII–7
51.
Barton SF, Langeland FF, Snabes MC, et al. Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery. Anesthesiology. 2002; 97: 306–14PubMedCrossRef
52.
Kenaan CA, Bikhazi GB, Deepika K, et al. Analgesic activity and safety of parecoxib in post-surgical patients: an interim report. Anesth Analg 2001; 92: S257
53.
Rasmussen GL, Steckner K, Hogue CW, et al. Intravenous parecoxib sodium foracute pain after orthopedic knee surgery. Am J Orthop 2002; 31: 336–43PubMed
54.
Stolz RR, Harris SI, Kuss ME, et al. Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects. Am J Gastroenterol 2002; 97: 65–71CrossRef
55.
Malan TP, Marsh G, Grossman E, et al. Parecoxib sodium, a new injectable COX-2 specific inhibitor, is opioid-sparing and improves pain relief in treating postoperative hip arthroplasty patients. J Pain Symptom Manage 2001; 2: 38
56.
Dallob A, Depre M, De Lepeleire N, et al. MK-0663: A highly selective inhibitor of COX-2 in humans. Ann Rheum Dis 2000; 59 Suppl. l: POS–279
57.
Ouellet M, Riendeau D, Percival MD. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc Natl Acad Sci USA 2001; 98: 14583–8PubMedCrossRef
58.
Kassahun K, McIntosh IS, Shou M, et al. Role of human cytochrome P450 3A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos 2001; 29: 813–20PubMed
59.
Chauret N, Yergey JA, Brideau C, et al. In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663). Bioorg Med Chem Lett 2001; 11: 1059–62PubMedCrossRef
60.
Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988; 15: 1833–40PubMed
61.
Gottesdiener K, Schnitzer T, Fisher C, et al. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology 2002; 41: 1052–61PubMedCrossRef
62.
Leung AT, Malmstrom K, Gallacher AE, et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin 2002; 18: 49–58PubMedCrossRef
63.
Matsumoto AK, Melian A, Mandel DR, et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol 2002; 29: 1623–30PubMed
64.
Schumacher HR Jr, Boice JA, Daikh DI, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ 2002; 324: 1488–92PubMedCrossRef
65.
Hunt RH, Callegari P, Bowen B, et al. COX-2 specific inhibition with MK-0663 120 mg once daily over 4 weeks did not increase fecal blood loss: a controlled study with placebo and ibuprofen 800 mg TID. Ann Rheum Dis 2001; 60 Suppl. 1: SAT0051
66.
Marshall PJ, Berry C, Wasvary J. The in vitro and in vivo selectivity of COX189, a new and highly selective inhibitor of COX-2. Ann Rheum Dis 2002; 61 Suppl. 1: 259
67.
Warner TD, Pairet M, Van Ryn J. Test systems for inhibitors of cyclooxygenase-1 and cyclooxygenase-2. In: Vane JR, Botting RM, editors. Therapeutic roles of selective COX-2 inhibitors. London: William Harvey Press, 2001: 76–94
68.
Rordorf C, Scott G, Blood P, et al. Treatment of healthy subjects with COX189, a COX-2 selective inhibitor; endoscopic evidence for lack of gastro-duodenal erosions compared to non-selective NSAID. Ann Rheum Dis 2002; 61 Suppl. 1: 128
69.
Scott G, Rordorf C, Blood P, et al. Dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of COX189 in healthy subjects. Ann Rheum Dis 2002; 61 Suppl. 1: 244
70.
Rordorf C, Scott G, Milosavljev S, et al. Steady state pharmacokinetics, pharmacodynamics, safety and tolerability of COX189 in healthy subjects. Ann Rheum Dis 2002; 61 Suppl. 1: 420
71.
Scott G, Rordorf C, Milosavljev S, et al. Pharmacokinetics and pharmacodynamics of COX189 in patients with knee or hip primary osteoarthritis. Ann Rheum Dis 2002; 61 Suppl. 1: 128
72.
Moore A, Della Casa Alberighi O, Gitton X, et al. Responder rate of COX189 in osteoarthritis: a multi-national study. Ann Rheum Dis 2002; 61 Suppl. 1: 137
73.
Atherton CT, Jones JIW, McKaig BC, et al. COX189, a new highly selective COX-2 inhibitor that lacks the ability of naproxen to enhance small bowel permeabilty. Ann Rheum Dis 2002; 61 Suppl. 1: 245
74.
Hawkey CJ, Karateev D, Codreanu C, et al. Improved upper gastrointestinal (UGI) safety and tolerability of a new COXIB, COX189, compared with ibuprofen in osteoarthritis patients. Ann Rheum Dis 2002; 61 Suppl. 1: 126
75.
Schnitzer T, Geusens P, Hasler P, et al. Efficacy and safety of COX189 in osteoarthritis: a multinational study. Arthritis Rheum 2000; 43: S336CrossRef
76.
Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The Class study: a randomized controlled trial. JAMA 2000; 284: 1247–55
77.
78.
Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954–9PubMedCrossRef
79.
Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001; 104: 2280–8PubMedCrossRef
80.
Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosa-noids. J Pharmacol ExpTher 1999; 289: 735–41
81.
McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999; 96: 272–7PubMedCrossRef
82.
83.
Metadaten
Titel
The Second Generation of COX-2 Inhibitors
What Advantages Do the Newest Offer?
verfasst von
Dr Dirk O. Stichtenoth
Jürgen C. Frölich
Publikationsdatum
01.01.2003
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 1/2003
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200363010-00003

Weitere Artikel der Ausgabe 1/2003

Drugs 1/2003 Zur Ausgabe

Adis Drug Evaluation

Micronised Purified Flavonoid Fraction

Therapy In Practice

Responsible Prescribing of Opioids for the Management of Chronic Pain

Adis Drug Evaluation

Pantoprazole

Adis Drug Evaluation

Nesiritide

Leading Article

Intestinal Graft-Versus-Host Disease